Is there a case for eculizumab for pediatric renal transplantation?

Publisher： John Wiley & Sons Inc

E-ISSN： 1399-3046|22|2|petr.13128-petr.13128

ISSN： 1397-3142

Source： PEDIATRIC TRANSPLANTATION, Vol.22, Iss.2, 2018-03, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A case of thrombotic micro‐angiopathy after heart transplantation successfully treated with eculizumab

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 7, 2015-07 ,pp. : 878-880

John Wiley & Sons Inc

Access to resources Recommend Favorite

A prospective randomized, controlled trial of eculizumab to prevent ischemia‐reperfusion injury in pediatric kidney transplantation

By  

PEDIATRIC TRANSPLANTATION, Vol. 22, Iss. 2, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cytomegalovirus‐induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 9, 2015-09 ,pp. : 1121-1125

John Wiley & Sons Inc

Access to resources Recommend Favorite

Should we monitor mycophenolic acid plasma levels in pediatric renal transplantation?

By  

PEDIATRIC TRANSPLANTATION, Vol. 1397-3142, Iss. 7, 2015-11 ,pp. : 665-666

John Wiley & Sons Inc

Access to resources Recommend Favorite

Should we monitor mycophenolic acid plasma levels in pediatric renal transplantation?

By  

PEDIATRIC TRANSPLANTATION, Vol. 19, Iss. 7, 2015-11 ,pp. : 665-666

John Wiley & Sons Inc

Access to resources Recommend Favorite